Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Risedronate Sodium
Generic Name
Risedronate Sodium
Active Ingredient
RisedronateCategory
Other
Salt Form
Sodium Monohydrate
Variants
24
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30.1 mg/1 | TABLET, FILM COATED | ORAL | 59762-0405 |
| 35 mg/1 | TABLET, FILM COATED | ORAL | 71205-714 |
| 150 mg/1 | TABLET, FILM COATED | ORAL |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Risedronate Sodium, you must consult a qualified healthcare professional.
| 30 mg/1 | TABLET, FILM COATED | ORAL | 65862-518 |
| 35 mg/1 | TABLET, FILM COATED | ORAL | 65862-519 |
| 5 mg/1 | TABLET, FILM COATED | ORAL | 0093-3099 |
| 35 mg/1 | TABLET, FILM COATED | ORAL | 33342-109 |
| 35 mg/1 | TABLET, FILM COATED | ORAL | 0093-3098 |
| 30 mg/1 | TABLET, FILM COATED | ORAL | 0093-3100 |
| 5 mg/1 | TABLET, FILM COATED | ORAL | 47335-666 |
| 129 mg/1 | TABLET, FILM COATED | ORAL | 59762-0406 |
| 150 mg/1 | TABLET, FILM COATED | ORAL | 65862-870 |
+ 12 more variants
Detailed information about Risedronate Sodium
Risedronate is a pyridinyl bisphosphonate medication used to treat and prevent various forms of osteoporosis and Paget's disease of bone by regulating bone turnover.
The dosage of risedronate varies significantly depending on the condition being treated. Your healthcare provider will determine the schedule that is best for you.
Risedronate is not approved for use in pediatric patients. The safety and effectiveness of risedronate in children and adolescents under the age of 18 have not been established. Use in children with conditions like osteogenesis imperfecta has been studied in clinical trials, but it remains an off-label use that must be strictly managed by specialized pediatric endocrinologists.
No dosage adjustment is necessary for patients with mild to moderate renal impairment (Creatinine Clearance [CrCl] ≥ 30 mL/min). However, risedronate is not recommended for patients with severe renal impairment (CrCl < 30 mL/min) because there is limited clinical experience in this population and the drug is primarily cleared by the kidneys.
Since risedronate is not metabolized by the liver, no dosage adjustments are required for patients with hepatic (liver) impairment.
In clinical trials, no overall differences in efficacy or safety were observed between patients over age 65 and younger patients. No age-based dose adjustment is required, provided renal function is adequate.
Proper administration is the most critical aspect of taking risedronate. Failure to follow these steps can result in the drug not working or causing severe damage to the esophagus.
Symptoms of a risedronate overdose may include a significant drop in calcium levels (hypocalcemia), which can cause muscle cramps, spasms, or numbness. It may also cause an upset stomach or heartburn. If an overdose occurs, drink a full glass of milk and seek emergency medical attention immediately. Do not induce vomiting, and do not lie down.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as bone density loss can recur quickly after discontinuation.
Most patients tolerate risedronate well, but some experience mild to moderate side effects. These typically occur during the first few weeks of treatment and may subside as the body adjusts.
Risedronate is a powerful medication that requires careful management. Patients must be able to strictly follow the administration instructions to avoid serious injury to the upper gastrointestinal tract. It is not suitable for everyone, particularly those with certain esophageal or kidney conditions.
There are currently no FDA black box warnings for Risedronate. However, it carries significant warnings regarding gastrointestinal irritation and mineral metabolism that must be respected.
There are no absolute drug-drug contraindications where risedronate cannot be used under any circumstances, but it should never be taken at the same time as any other oral medication. Taking other drugs simultaneously will prevent risedronate from being absorbed.
There are specific situations where risedronate must NEVER be used because the risks far outweigh any potential benefits.
Pregnancy Category C. There are no adequate and well-controlled studies of risedronate in pregnant women. Animal studies have shown that risedronate can cross the placental barrier and result in skeletal variations and decreased bone ossification in the fetus. Furthermore, bisphosphonates are incorporated into the bone matrix, from which they are gradually released over periods of weeks to years. There is a theoretical risk that if a woman becomes pregnant years after stopping risedronate, the fetus could still be exposed to the drug released from the mother's bones. Risedronate should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
It is not known whether risedronate is excreted in human milk. In animal studies, small amounts of risedronate were found in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from risedronate, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Risedronate is a nitrogen-containing bisphosphonate. Its primary molecular target is the enzyme farnesyl pyrophosphate (FPP) synthase within the mevalonate pathway of osteoclasts. By inhibiting this enzyme, risedronate prevents the prenylation (attachment of lipid tails) of small GTP-binding proteins like Rab, Rho, and Rac. These proteins are essential for the osteoclast's internal signaling and the maintenance of its 'ruffled border'—the specialized cell membrane that secretes acid to dissolve bone. Without a functional ruffled border, the osteoclast cannot resorb bone and eventually dies. This results in a significant decrease in the rate of bone resorption, which allows the bone-forming osteoblasts to catch up and increase the overall mineral density of the bone.
Risedronate begins to affect bone turnover markers within the first month of treatment, with maximal effects usually seen within 3 to 6 months. The drug's effect is dose-dependent. In patients with Paget's disease, risedronate leads to a significant decrease in serum alkaline phosphatase (a marker of bone turnover), often returning it to the normal range. The duration of effect is long-lasting due to the drug's persistence in the bone matrix; even after stopping the drug, bone resorption remains suppressed for several months.
Common questions about Risedronate Sodium
Risedronate is primarily used to treat and prevent osteoporosis in postmenopausal women and in men, as well as to manage glucocorticoid-induced osteoporosis in people taking steroid medications. It is also used to treat Paget's disease of the bone, a condition that causes bones to become fragile and deformed. By slowing down the cells that break down bone, risedronate helps to increase bone density and significantly reduce the risk of spine and hip fractures. Your doctor will determine the appropriate dose based on your specific bone health needs and medical history. It is an essential therapy for those at high risk of skeletal complications.
The most common side effects of risedronate include gastrointestinal issues such as stomach pain, nausea, diarrhea, and indigestion. Some patients also report mild musculoskeletal pain, including aching in the joints or muscles, and occasional headaches. These symptoms are often mild and occur most frequently when first starting the medication. To minimize stomach-related side effects, it is crucial to follow the administration instructions, such as staying upright for 30 minutes after taking the pill. If these side effects become severe or persistent, you should contact your healthcare provider for guidance.
There is no known direct interaction between risedronate and alcohol that makes the drug toxic. However, chronic and excessive alcohol consumption is a known risk factor for developing osteoporosis and can interfere with your body's ability to build new bone. Furthermore, both alcohol and risedronate can irritate the lining of the stomach, so combining them may increase your risk of developing gastritis or an ulcer. It is generally recommended to consume alcohol only in moderation while being treated for bone loss. Always discuss your lifestyle habits with your doctor to ensure the best results from your treatment.
Risedronate is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. It is classified as Pregnancy Category C, meaning animal studies have shown potential harm to the developing skeleton, but there are no adequate studies in humans. Because the drug stays in the bone for a very long time, there is a theoretical concern about exposure even if the drug was stopped before conception. Women of childbearing age should discuss their future pregnancy plans with their doctor before starting this medication. If you become pregnant while taking risedronate, notify your healthcare provider immediately.
Risedronate begins to work at the cellular level almost immediately after the first few doses, but its effects on bone density take time to measure. Blood and urine tests for bone turnover markers usually show significant changes within 1 to 3 months of starting therapy. However, a noticeable increase in bone mineral density (BMD) as measured by a DXA scan typically takes at least 12 to 24 months of consistent use. The primary goal of the medication is to reduce fracture risk, which is a long-term benefit. It is important to continue taking the medication exactly as prescribed, even if you do not 'feel' it working.
You can stop taking risedronate without experiencing immediate withdrawal symptoms, as it does not cause physical dependence. However, stopping the medication will cause the bone-protective benefits to gradually disappear, and your rate of bone loss will likely return to its pre-treatment level. Many doctors recommend a 'drug holiday' after 3 to 5 years of use for certain patients, but this should only be done under strict medical supervision. Never stop your osteoporosis treatment without consulting your doctor, as they may need to start a different medication to maintain your bone density. A planned discontinuation is always safer than stopping abruptly on your own.
If you miss a dose of risedronate, the action depends on your specific dosing schedule. For a weekly 35 mg dose, take the missed pill the next morning after you remember, then return to your regular day the following week. For a monthly 150 mg dose, if your next scheduled dose is more than 7 days away, take the missed pill the next morning; if it is less than 7 days away, skip the missed dose entirely. Never take two tablets on the same day to make up for a missed one. Always follow the specific 'missed dose' instructions provided by your pharmacist or in the medication guide.
Weight gain is not a recognized or common side effect of risedronate based on extensive clinical trial data. If you experience significant or rapid weight gain while taking this medication, it is likely due to other factors, such as changes in diet, physical activity, or other medications you may be taking (like corticosteroids). Some patients may experience bloating or fluid retention, which can feel like weight gain, but this is usually related to gastrointestinal upset. If you are concerned about weight changes, discuss them with your healthcare provider to identify the underlying cause. Maintaining a healthy weight is actually beneficial for overall bone health and mobility.
Risedronate can be taken with other medications, but timing is the most critical factor. It must be taken on an empty stomach with plain water at least 30 to 60 minutes before any other oral medications, including vitamins and antacids. Calcium, magnesium, and iron supplements are particularly problematic because they bind to risedronate and prevent it from being absorbed into your bloodstream. There is also an increased risk of stomach irritation if risedronate is used alongside NSAIDs like ibuprofen or aspirin. Always provide your doctor with a full list of your current medications to check for potential interactions.
Yes, risedronate sodium is widely available as a generic medication in various strengths, including the 5 mg daily, 35 mg weekly, and 150 mg monthly tablets. The generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name version (Actonel). Generic risedronate is typically much more affordable than the brand-name equivalent and is covered by most insurance plans. However, the delayed-release version (Atelvia) may have different generic availability depending on your region. Consult your pharmacist to see if a generic version is appropriate for your prescription.
While rare, some side effects are severe and require immediate medical intervention.
> Warning: Stop taking Risedronate and call your doctor immediately if you experience any of these.
The primary concern with long-term use (typically more than 5 years) is the over-suppression of bone turnover. While risedronate prevents fractures by slowing bone loss, if the 'remodeling' process is slowed too much for too long, the bone may become 'brittle' rather than strong. This is why many doctors suggest a 'drug holiday' (a temporary break from the medication) after 3 to 5 years of continuous use for patients at lower risk of fracture. Long-term use is also the primary risk factor for the atypical femur fractures mentioned above.
No FDA black box warnings for Risedronate. However, the FDA has issued multiple safety communications regarding the risks of atypical femur fractures and osteonecrosis of the jaw, which are considered 'class effects' for all bisphosphonates.
Report any unusual symptoms to your healthcare provider. It is often helpful to keep a diary of any symptoms you experience after starting the medication to discuss at your next follow-up appointment.
To ensure risedronate is working safely and effectively, your doctor may order the following:
Risedronate generally does not affect the ability to drive or operate heavy machinery. However, if you experience dizziness or eye inflammation (rare side effects), you should avoid these activities until the symptoms resolve.
There is no direct chemical interaction between alcohol and risedronate. However, excessive alcohol consumption is a risk factor for developing osteoporosis and can also increase the risk of gastric irritation. It is generally recommended to limit alcohol intake while being treated for bone loss.
Unlike some medications, risedronate does not need to be 'tapered' off. However, once you stop taking it, the protective effect on your bones will gradually diminish over time. Do not stop the medication without a plan from your doctor, as they may want to monitor your bone density more closely or switch you to a different therapy.
> Important: Discuss all your medical conditions with your healthcare provider before starting Risedronate, especially if you have a history of stomach ulcers, anemia, or kidney disease.
Food is the primary 'interactor' for risedronate.
For each major interaction, the management strategy is usually timing. By ensuring risedronate is taken alone on an empty stomach, most interactions can be avoided.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and antacids.
These are conditions where the doctor must carefully weigh the risks and benefits before prescribing risedronate:
While not common, patients who have had a severe allergic reaction (like angioedema or anaphylaxis) to other bisphosphonates (such as alendronate/Fosamax, ibandronate/Boniva, or zoledronic acid/Reclast) may be at higher risk for a similar reaction to risedronate. This is known as cross-sensitivity within the bisphosphonate class.
> Important: Your healthcare provider will evaluate your complete medical history, including your ability to follow the strict dosing instructions, before prescribing Risedronate.
A large percentage of patients in risedronate clinical trials (over 60%) were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Risedronate is highly effective in the elderly at reducing the risk of hip fractures, which is a major cause of morbidity and mortality in this age group. However, doctors must be cautious of the higher prevalence of renal impairment and polypharmacy (taking multiple medications) in the elderly.
No dosage adjustment is needed for patients with hepatic impairment. The liver does not play a role in the clearance or metabolism of risedronate.
> Important: Special populations, particularly pregnant women and those with kidney disease, require individualized medical assessment and frequent monitoring when considering bisphosphonate therapy.
| Parameter | Value |
|---|---|
| Bioavailability | ~0.63% (Fasted) |
| Protein Binding | ~24% |
| Half-life (Terminal) | ~480–561 hours |
| Tmax | 1 hour |
| Metabolism | None |
| Excretion | Renal (Unchanged) |
Risedronate is classified as a Bisphosphonate. Specifically, it is a second-generation (nitrogen-containing) bisphosphonate. Related medications in this class include alendronate (Fosamax), ibandronate (Boniva), and zoledronic acid (Reclast/Zometa). Within this class, risedronate is noted for having a high potency for FPP synthase inhibition while maintaining a relatively low affinity for hydroxyapatite compared to zoledronate, which some researchers believe may allow for better distribution throughout the bone tissue.